Despite Turning Point USA's claims that the audio and accompanying videos had been taken down, the audio is still live on the ...

Aaron McDade is a breaking news reporter for Investopedia. He is an experienced journalist who has covered everything from the latest in business and tech news to sports and international news like ...

Eli Lilly’s latest attempt to strengthen its genetic medicine offering has seen the Big Pharma team up with Profluent to develop AI-designed recombinases to address diseases with severe unmet needs.

Eli Lilly said on Monday it would buy privately held cancer drug developer Ajax Therapeutics for up to $2.3 billion in cash, as the U.S. drugmaker looks to expand its oncology pipeline. Lilly has been ...

PASCO COUNTY, Fla. – The Pasco Sheriff’s Office is searching for 14-year-old Lilly Conway, a missing and runaway teenager. Conway was last seen at approximately 10:05 p.m. on March 17 at the Circle K ...

Eli Lilly & Co.’s new weight-loss pill Foundayo has gotten off to a sluggish start, according to new prescription data, an early sign of the challenge the drugmaker will have as it tries to catch up ...

April 24 (Reuters) - Eli Lilly's (LLY.N), opens new tab newly launched weight-loss pill had a modest second week, analysts said on Friday, as competition with Danish rival Novo Nordisk (NOVOb.CO), ...

Eli Lilly LLY is set to release its first-quarter 2026 earnings report on April 30. Here’s Morningstar’s take on what to look for in Lilly’s earnings and the outlook for its stock. With its 3-star ...

Eli Lilly announced Monday it will acquire Boston-based Kelonia Therapeutics with an initial payment of $3.25 billion, as the pharmaceuticals giant looks to bolster its position in the global cancer ...

Investors often mistake share price for valuation. While Eli Lilly's stock price looks expensive on the surface, the company's underlying valuation metrics are quite modest. Eli Lilly stock might ...

Eli Lilly’s most recent acquisition shows its aspirations beyond weight loss drugs. There’s time for investors to get in and buy the stock.

Just a few months after ripping up the central nervous system-focused portion of its RIPK1 deal with Rigel Pharmaceuticals, Eli Lilly has now thrown out the rest of the pact too. Lilly notified Rigel ...